US Pharmacist June 2015 : Tip 1

Trusted to take a bite out of G-CSF acquisition costs * GRANIX ® has gained >34% share of the US short-acting G-CSF hospital market in its first 17 months 1 See what’s new inside! Indication » GRANIX is a leukocyte growth factor indicated for reduction in the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. Important Safety Information » Splenic rupture: Splenic rupture, including fatal cases, can occur following the administration of human granulocyte colony-stimulating factors (hG-CSFs). Discontinue GRANIX and evaluate for an enlarged spleen or splenic rupture in patients who report upper abdominal or shoulder pain after receiving GRANIX. *Based on wholesale acquisition cost (WAC) of all short-acting G-CSF products as of March 2015. WAC represents published catalogue or list prices and may not represent actual transactional prices. Please contact your supplier for actual prices. Please see reverse side for additional Important Safety Information and brief summary of Full Prescribing Information on page adjacent to our ad inside.

Next Page

Publication List
Using a screen reader? Click Here